This web only provides the extract of this article. If you want to read the figures and tables, please reference the PDF full text on Blackwell Synergy. Thank you.
- Original Article -
Postprandial triglyceride metabolism in elderly men with
subnormal testosterone levels
Ingvild Agledahl1,2, John-Bjarne
Hansen2, Johan Svartberg1,3
1Department of Medicine, University Hospital of North Norway, Tromsø 9038, Norway
2Center for Atherothrombotic Research in Tromsø (CART), Institute of Clinical Medicine, University of Tromsø, Tromsø
9037, Norway
3Institute of Clinical Medicine, University of Tromsø, Tromsø 9037, Norway
Abstract
Aim: To investigate the level of postprandial triglycerides (TG)s in elderly men with subnormal testosterone level
(¡Ü 11.0 nmol/L) compared to men with normal testosterone level (> 11.0 nmol/L).
Methods: Thirthy-seven men with subnormal and 41 men with normal testosterone aged 60_80 years underwent an oral fat load and TG levels were
measured fasting and 2, 4, 6 and 8 h afterwards.
Results: Men with subnormal testosterone had significantly higher
body mass index (BMI) and waist circumference (P
< 0.001) than men with normal testosterone. They had
significantly higher area under curve (AUC, P
= 0.037), incremental area under curve (AUCi,
P = 0.035) and TG response (TGR, P = 0.014) for serum-TG and significantly higher AUC
(P = 0.023), AUCi (P = 0.023) and TGR
(P = 0.014) for chylomicron-TG compared to men with normal testosterone level. Adjusting for waist circumference erased the
significant differences between the groups in postprandial triglyceridemia.
Conclusion: Men with subnormal testosterone have increased postprandial TG levels indicating an impaired metabolism of postprandial TG-rich lipoproteins
(TRL), which may add to an unfavourable lipid profile and promote development of atherosclerosis.
(Asian J Androl 2008 Jul; 10: 542_549)
Keywords: testosterone; sex hormone-binding globulin; postprandial triglycerides; abdominal obesity; waist circumference
Correspondence to: Dr Ingvild Agledahl, Institute of Clinical Medicine, University of Tromsø, Tromsø 9037, Norway.
Tel: +47-9585-4135, +47-7764-4378 Fax: +47-7764-4650
E-mail: ingvild.agledahl@fagmed.uit.no
Received 2007-09-21 Accepted 2008-01-11
DOI: 10.1111/j.1745-7262.2008.00387.x
1 Introduction
Abnormal lipid levels in fasting subjects are associated with atherosclerosis [1, 2]. We do, however, spend most
of our lives in a postprandial state, between the consumption of regular meals. In the postprandial state, our vessel
walls are exposed to triglyceride (TG)-rich dietary lipoproteins and the magnitude of postprandial triglyceridemia is
associated with cardiovascular disease [3]. Remnants of postprandial lipoproteins are shown to rapidly penetrate
arterial tissue and accumulate in the subendothelial space, showing that atherosclerosis is in part a postprandial
phenomenon [4]. Men have a higher incidence of cardiovascular disease (CVD) than women in the same age group,
and they have a less favourable lipid profile than women, with higher levels of TGs and lower levels of high density
lipoprotein (HDL) cholesterol [5]. Therefore, it has been
suggested that testosterone might influence the
development of CVD [6]. However, most cross-sectional
studies in fasting men show a negative association between
endogenous total testosterone and TG [7] and a positive
association between endogenous total testosterone and
HDL cholesterol [8]. Low endogenous testosterone
levels are also associated with atherosclerosis
[9_11]. However, so far no relation between endogenous
testosterone and cardiovascular events has been reported
[6].
Recently, epidemiological data from the Tromsø study
showed increased non-fasting TG during the day in men
with lower total testosterone compared to men with higher
total testosterone [12]. To further investigate the
relationship between endogenous testosterone and
postprandial TG levels, we performed a case-control study in
elderly men with subnormal and normal total
testosterone to compare postprandial TG levels after intake of a
standard oral fat load.
2 Materials and methods
2.1 Participants
A sub-group of men participating in the study "Older
Men and Testosterone", which will be presented in a
separate publication, were included in this study. Briefly,
based on total testosterone levels from the fifth survey
of the Tromsø study in 2001 [12], men aged
60_80 years in 2005 were asked to participate in a study
with the objective of evaluating subnormal testosterone
levels in a variety of aspects. Men with persistent
subnormal testosterone (¡Ü 11.0 nmol/L) or normal
testosterone (> 11.0 nmol/L) in both 2001 and 2005 were
included in the study. In this sub-study, 37 men with
persistent subnormal testosterone and 41 men with
persistent normal testosterone accepted to participate in a
fat-tolerance test with the objective of investigating
postprandial TG-rich lipoproteins.
The Regional Committee for Research and Ethics approved the study, and all participants gave written,
informed consent.
2.2 Methods
The study was performed at the Clinical Research
Unit at the University Hospital of North Norway. A
physical examination and a complete medical history,
including the use of prescription medication, were conducted.
Height, weight and waist circumference were measured
with the participants in light clothing without shoes and
body mass index (BMI) as weight per height squared
(kg/m2) was calculated. Blood pressure was measured
while the subject was in a seated position using an
automatic device (Propaq 102 El, Protocol Systems, Beaverton,
Oregon, USA), three recordings at 1 min intervals were
conducted, and the mean of the last two values was used
in this report. Baseline blood samples were drawn in the
morning at 07:45 hours from an antecubital vein on the
right arm after 12 h overnight fasting, using an 18-gauge
needle in a vacutainer system with minimal stasis.
Serum was prepared by clotting whole blood in a glass
tube at room temperature for 30 min, centrifuged at 2
000 × g for 15 min at 20ºC, and then analyzed using standard
laboratory procedures at the Department of Clinical
Chemistry, University Hospital of North Norway, Tromsø, Norway. Total testosterone was measured by
electrochemical luminescence immunoassay on Modular Analytics SWA (F. Hoffmann-La Roche, Basel,
Switzerland). The intra-assay and inter-assay coefficients
of variance (CV) for testosterone were 4.6% and 5.9%,
respectively. Sex hormone-binding globulin (SHBG) was
analyzed by chemoluminescence immunoassay on Immulite 2000 (Diagnostic Product, Los Angeles, CA,
USA). The intra-assay and inter-assay CV for SHBG were
3.4% and 6.8%, respectively. Free testosterone was
calculated from total testosterone and sex hormone-binding
globulin (SHBG) according to Vermeulen et
al. [13].
2.2.1 Fat-tolerance test
A fat-tolerance test was conducted using a test meal
prepared from standard porridge cream containing 70%
calories of fat, of which 66% was saturated fat, 32% was
monounsaturated fat and 2% was polyunsaturated fat [14].
A freshly prepared test meal was served with two
teaspoons of sugar, cinnamon and two glasses (150 mL) of
sugar-free juice. The participants were served a
weight-adjusted meal (1 g fat per kg body weight) at 08:00 hours
and the meal was consumed within a 15-min period. The
participants were allowed a 500-mL calorie-free beverage
and one apple during the following 8 h. Blood samples
for isolation of chylomicrons and serum were collected
before the meal and every second hour over the next
8 h.
2.2.2 Isolation of chylomicrons
Chylomicrons were isolated by overlayering 8 mL
EDTA plasma with 5 mL of NaCl gradient (density
1 006 kg/L NaCl solution with 0.01% EDTA) in a nitrate
cellulose tube (Beckman Instruments, Palo Alto, CA,
USA) and centrifuged in a Beckman SW40 Ti swinging
bucket rotator at 20 000 × g for 1 h at 20ºC. The
chylomicrons were carefully removed by aspiration, divided
into three aliquots in cryovials and frozen at _70ºC until
further analysis.
2.2.3 Serum lipid measurements
Serum lipids were analyzed on an ABX Pentra 400
(Horiba ABX Diagnostics, Montpellier, France) with
reagents from Horiba ABX Diagnostics (Montpellier,
France). Total cholesterol (CHOD-PAP) was measured
using an enzymatic photometric method and TG (GPO-PAP) was measured using an enzymatic colorimetric
method. Low-density lipoprotein cholesterol and HDL
cholesterol were measured directly using selective
inhibition colorimetric assays (Horiba ABX Diagnostics,
Montpellier, France).
2.2.4 Lipoprotein lipase and hepatic lipase activity
Eight hours after ingestion of the test meal, blood
was drawn into lithium heparin vacutainers (BD Vacutainer Systems, Belliver Industrial Estate, Plymouth,
UK) containing heparin as anticoagulant and the heparinised blood was immediately placed on ice.
Unfractionated heparin was given as a bolus injection
(100 IU/kg body weight) on the contra lateral arm to
mobilize lipoprotein lipase (LPL) and hepatic lipase (HL)
from the endothelial surface into the circulation. A
second blood sample was collected exactly 15 min after
heparin administration and immediately placed on ice.
Heparinised plasma was recovered within 30 min by
centrifugation at 2 000 × g for 15 min at 4ºC, divided into
aliquots of 0.5 mL in cryovials and frozen until further
analysis.
Lipoprotein lipase activity and HL activity were
determined as described by Olivecrona et al.
[15]. In short, sonicated emulsion of ³H-oleic labeled triolein acid in 10%
Intralipid (Fresenius Kabi, Halden, Norway) was used as
substrate in the LPL cholesterol assay. Samples were
preincubated for 2 h on ice with 0.5 volume goat
antibodies to HL to suppress HL activity. For determination
of HL activity, sonicated emulsion of ³H-oleic labeled
triolein acid was used as substrate. Samples were mixed
with 5 mol/L NaCl acid and 10% bovine serum albumin
to suppress LPL activity and to remove free fatty acids.
LPL activity and HL activity are expressed in mU/mL
corresponding to nmol of fatty acids released per
mL/min. The samples were quantified in duplicate and postheparin
plasma from pooled normal control people were used to
correct for inter-assay variation. Intra-assay and
inter-assay CV for post-heparin LPL activity were 1.9% and
9.3% respectively, and 1.9% and 7.5%, respectively, for
HL activity.
2.3 Statistics
Postprandial hypertriglyceridemia was assessed by
total area under the curve (AUC), incremental AUC (AUCi)
and triglyceride response (TGR), defined as the average
of the two highest postprandial TG concentrations
minus baseline concentrations, for serum-TG and
chylomicron-TG. Normal distribution was evaluated by
determination of skewness and histograms. AUC, AUCi and
TGR for serum-TG and chylomicron-TG and LPL and HL activity were not normally distributed and, therefore,
natural logarithmically transformed. After the
logarithmic transformation they were considered normally
distributed. Differences between the groups were
assessed using independent-samples t-tests. General
linear models for univariate analyses of variance were used
for adjustments. Multiple linear regression models were
used to assess independent predictors of AUC, AUCi and
TGR for serum-TG and chylomicron-TG. All analyses
were performed using SPSS for windows software (version 13.0, Chicago, IL, USA). All statistical tests were
two-tailed, with statistical significance defined as
P < 0.05.
3 Results
Characteristics of the participants are shown in
Table 1. As expected, men with subnormal testosterone
levels also had lower free testosterone levels. In addition,
SHBG was significantly lower in the men with
subnormal testosterone levels. There were no significant
differences between men with subnormal testosterone and
men with normal testosterone with regard to age, fasting
serum lipids, systolic blood pressure, diastolic blood
pressure, smoking status or self-reported history of CVD.
Men with subnormal testosterone had significantly higher
BMI (30.5 vs. 26.1 kg/m2,
P < 0.001) and waist circumference (109
vs. 95 cm, P < 0.001), and reported a higher
use of statins (P < 0.001).
Serum-TG and chylomicron-TG before and every second hour after ingestion of a standard fat meal are
shown in Figure 1. Table 2 shows that men with
subnormal testosterone had significantly higher AUC
(P = 0.037), AUCi
(P = 0.035) and TGR
(P = 0.014) for serum-TG and significantly higher AUC
(P = 0.023), AUCi
(P = 0.023) and TGR
(P = 0.014) for chylomicron-TG compared to men with normal testosterone
levels. After adjusting for waist circumference the
differences between the groups were no longer significant.
There was no difference between the groups in
pre-heparin or postheparin levels of LPL and HL activity
(Table 2). However, after adjusting for waist
circumference, postheparin LPL activity was significantly higher
in men with subnormal testosterone
(P = 0.012).
In multiple linear regression analyses (Table 3),
fasting TG, postheparin LPL activity and waist
circumference were independent predictors of AUC, AUCi and TGR
for serum-TG and of AUC and AUCi for chylomicron-TG. Fasting TG and postheparin LPL were independent
predictors of TGR for chylomicron-TG. Total
testosterone and SHBG (data not shown) were inversely
associated with AUC, AUCi and TGR for serum-TG and for
chylomicron-TG. These associations were lost after
waist circumference was added to the models. There
were no associations between free testosterone and
triglyceride-rich lipoproteins (TRL).
4 Discussion
In this case-control study of 78 elderly men, we
found that men with subnormal testosterone had
significantly higher postprandial concentrations of TRL than
men with normal testosterone. In addition, total
testosterone was negatively associated with postprandial
concentrations of TRL. Our results are unchallenged as we
have not found any previously reported fat-tolerance tests
performed in men with subnormal testosterone. However, in a study by Hislop
et al. [16], postprandial TGs were reduced after a standard fatty meal in body
builders using high dose androgens compared to controls not using androgens. In addition, cross-sectional
data on elderly men from Tromsø, showed that low
testosterone levels were associated with higher non-fasting
TG levels, suggesting that testosterone may influence
the TG metabolism [12]. Finally, other epidemiological
studies in both middle-aged and older men have also
reported an inverse relationship between total testosterone
and fasting TG [7, 17, 18].
In our study, men with subnormal testosterone had
increased waist circumference compared to men with
normal testosterone. Waist circumference was positively
associated with postprandial TGs and identified as an
independent predictor of postprandial TG levels. Our
results are supported by previous studies showing that
both increased BMI and visceral adipose tissue are
associated with increased postprandial TRL [19, 20].
Adjusting for abdominal obesity, as measured by waist
circumference, erased the significant differences in
postprandial TGs between the groups. These findings
suggest that there are interrelations between low testosterone,
postprandial TG concentrations and body fat distribution,
but our study design is not suitable for determining the
causal relations between these factors. It has been
suggested that age-related decline in testosterone might be
responsible for the changes in body fat and body fat
distribution seen in elderly men [21]. This is supported by
the observation that men with low testosterone have
increased abdominal obesity [22] and that low-dose
androgen treatment decreases abdominal fat mass in both
younger and older men, regardless of cause of the
decreased testosterone level [23]. In addition, in a 12-year
follow-up study, lower levels of testosterone was
predictive of central obesity [24]. In contrast, others have
suggested that obesity plays a causal role in the decline
of total and free testosterone [25], and that weight loss
in younger obese individuals is reported to partially
reverse low testosterone levels [26]. A recent publication
from the Rancho Bernardo cohort also reports that weight
loss in older men during a 10-year-period was
associated with higher testosterone levels, whereas weight gain
was associated with lower testosterone levels [27] .
Lipoprotein lipase hydrolyses TG in circulating TRL
[28], thereby removing TG from the bloodstream and
supplying underlying tissues with free fatty acids [29].
In abdominally obese men, supplementation with
testosterone decreases LPL activity [30, 31] and inhibits
uptake of fatty acids in subcutaneous abdominal adipocytes [30], thereby inhibiting abdominal obesity.
Therefore, reduced inhibition of LPL activity in
abdominal adipocytes in men with low testosterone might partly
explain their abdominal obesity. In our study,
endothelial-associated LPL, mobilized into circulation by heparin
administration, was not different between groups in crude
analysis, but significantly higher in men with subnormal
testosterone after adjustment for waist circumference.
Therefore, our findings support previous studies
showing an inhibitory effect of testosterone on LPL activity
[30, 31].
Endothelial-associated LPL in the capillary bed plays
a pivotal role in the metabolism of postprandial TRL [32].
Deficiency of LPL or its cofactor apoCII is known to
induce accumulation of chylomicrons in plasma, suggesting that triglyceride hydrolysis is important for
clearance of these particles [33, 34]. In agreement with
previous studies [35], postheparin LPL activity was found
to be an inverse and independent predictor of the
magnitude of postprandial hyperlipidemia in our study.
Statin treatment is known to reduce postprandial
triglyceridemia [36] in a dose dependent manner by
5%_30% [37]. In our study, 41% of the men with
subnormal testosterone used statins compared to 7% of the
men with normal testosterone. Therefore, it is likely
that the actual increase and delayed clearance of
postprandial TRL in men with subnormal testosterone is even
more pronounced. Because cholesterol is the precursor
of steroid hormones, it has been suggested that use of
statins might influence steroidogenesis, including gonadal
steroids production [38]. Previous studies have reported
that statin treatment has a neutral effect on [39] or causes
only a modest reduction in [40] testosterone. However,
the clinical relevance of statin treatment on testosterone
metabolism remains to be settled.
Increased and delayed postprandial hyperlipidemia
have been reported to be strong predictors of coronary
artery disease (CAD), verified by angiography in
middle-aged men with severe disease [41, 42]. Furthermore,
patients with CAD have increased levels and delayed
elimination of postprandial TRL [42], and the plasma
concentrations of postprandial remnants have been
related to the progression of coronary lesions [41].
Postprandial TRL are able to penetrate and retain in the
arterial wall [4], followed by uptake into macrophages to
form foam cells [43]. Therefore, increased
postprandial TRL in men with subnormal testosterone might
represent an additional unfavorable lipid disturbance that
might promote deve-lopment of atherosclerosis.
In summary, in this case-control study, men with
subnormal testosterone had increased postprandial
concentrations of TRL compared to men with normal
testosterone. Increased postprandial TRL might promote
atherosclerosis and constitute a risk factor of
cardiovascular disease in these men. Adjustment for waist
circumference erased the differences in postprandial TRL
between groups. Our study design is, however, not
suitable in settling the causal relations between testosterone,
abdominal obesity and postprandial TRL and
intervention studies with testosterone to men with subnormal
testosterone are warranted.
Acknowledgment
This study was supported by an independent grant
from the Center for Research in the Elderly in Tromsø,
Norway. We are indebted to the men who participated in
our study and to the staff at the Clinical Research Unit at
the University Hospital of North Norway and at the
Center for Atherothrombotic Research in Tromsø (CART)
Laboratory at the University of Tromsø. CART is
supported by an independent grant from Pfizer.
References
1 Pekkanen J, Linn S, Heiss G, Suchindran CM, Leon A, Rifkind
BM, et al. Ten-year mortality from cardiovascular disease in
relation to cholesterol level among men with and without
preexisting cardiovascular disease. N Engl J Med 1990; 322:
1700_707.
2 Lippel K, Tyroler H, Eder H, Gotto A, Jr. Vahouny G.
Relationship of hypertriglyceridemia to atherosclerosis.
Arteriosclerosis 1981; 1: 406_17.
3 Patsch JR, Miesenbock G, Hopferwieser T, Muhlberger V,
Knapp E, Dunn JK, et al. Relation of triglyceride metabolism
and coronary artery disease. Studies in the postprandial state.
Arterioscler Thromb 1992; 12: 1336_45.
4 Proctor SD, Mamo JC. Retention of fluorescent-labelled
chylomicron remnants within the intima of the arterial
wall-evidence that plaque cholesterol may be derived from
post-prandial lipoproteins. Eur J Clin Invest 1998; 28:
497_503.
5 Godsland IF, Wynn V, Crook D, Miller NE. Sex, plasma
lipoproteins, and atherosclerosis: prevailing assumptions and
outstanding questions. Am Heart J 1987; 114:
1467_503.
6 Liu PY, Death AK, Handelsman DJ. Androgens and
cardiovascular disease. Endocr Rev 2003; 24:
313_40.
7 Lichtenstein MJ, Yarnell JW, Elwood PC, Beswick AD,
Sweetnam PM, Marks V, et al. Sex hormones, insulin, lipids,
and prevalent ischemic heart disease. Am J Epidemiol 1987;
126: 647_57.
8 Khaw KT, Barrett-Connor E. Endogenous sex hormones, high
density lipoprotein cholesterol, and other lipoprotein fractions
in men. Arterioscler Thromb 1991; 11: 489_94.
9 Svartberg J, von Muhlen D, Mathiesen E, Joakimsen O, Bonaa
KH, Stensland-Bugge E. Low testosterone levels are
associated with carotid atherosclerosis in men. J Intern Med 2006;
259: 576_82.
10 Hak AE, Witteman JC, de Jong FH, Geerlings MI, Hofman A,
Pols HA. Low levels of endogenous androgens increase the risk
of atherosclerosis in elderly men: the Rotterdam study. J Clin
Endocrinol Metab 2002; 87: 3632_9.
11 van den Beld AW, Bots ML, Janssen JA, Pols HA, Lamberts
SW, Grobbee DE. Endogenous hormones and carotid
atherosclerosis in elderly men. Am J Epidemiol 2003; 157:
25_31.
12 Agledahl I, Skjaerpe PA, Hansen JB, Svartberg J. Low serum
testosterone in men is inversely associated with non-fasting
serum triglycerides: The Tromsø study. Nutr Metab
Cardiovasc Dis 2007 Jun 7 [Epub ahead of print].
13 Vermeulen A, Verdonck L, Kaufman JM. A critical evaluation
of simple methods for the estimation of free testosterone in
serum. J Clin Endocrinol Metab 1999; 84:
3666_72.
14 Nordoy A, Bonaa KH, Sandset PM, Hansen JB, Nilsen H.
Relationship between apolipoprotein E polymorphism,
postprandial hyperlipemia and hemostatic variables in patients
with combined hyperlipemia. Nutr Metab Cardiovasc Dis
2000; 10: 15_23.
15 Olivecrona T, Olivecrona G. Lipoprotein lipase and hepatic
lipase in lipoprotein metabolism. In: Betteridge DJ, Illingworth
DR, Shepard J, editors. Lipoprotein In Health and Disease.
London: Arnold. 1999; p223_46.
16 Hislop MS, St Clair Gibson A, Lambert MI, Noakes TD,
Marais AD. Effects of androgen manipulation on postprandial
triglyceridaemia, low-density lipoprotein particle size and
lipoprotein(a) in men. Atherosclerosis 2001; 159:
425_32.
17 Barrett-Connor E, Khaw KT. Endogenous sex hormones and
cardiovascular disease in men. A prospective population-based
study. Circulation 1988; 78: 539_45.
18 Chen RY, Wittert GA, Andrews GR. Relative androgen
deficiency in relation to obesity and metabolic status in older men.
Diabetes Obes Metab 2006; 8: 429_35.
19 Couillard C, Bergeron N, Prud'homme D, Bergeron J, Tremblay
A, Bouchard C, et al. Postprandial triglyceride response in
visceral obesity in men. Diabetes 1998; 47:
953_60.
20 Lewis GF, O'Meara NM, Soltys PA, Blackman JD, Iverius
PH, Druetzler AF, et al. Postprandial lipoprotein metabolism
in normal and obese subjects: comparison after the vitamin A
fat-loading test. J Clin Endocrinol Metab 1990; 71:
1041_50.
21 Blouin K, Despres JP, Couillard C, Tremblay A, Prud'homme
D, Bouchard C, et al. Contribution of age and declining
androgen levels to features of the metabolic syndrome in men.
Metabolism 2005; 54: 1034_40.
22 Svartberg J, von Muhlen D, Sundsfjord J, Jorde R. Waist
circumference and testosterone levels in community dwelling
men. The Tromsø study. Eur J Epidemiol 2004; 19:
657_63.
23 Snyder PJ, Peachey H, Hannoush P, Berlin JA, Loh L, Lenrow
DA, et al. Effect of testosterone treatment on body
composition and muscle strength in men over 65 years of age. J Clin
Endocrinol Metab 1999; 84: 2647_53.
24 Khaw KT, Barrett-Connor E. Lower endogenous androgens
predict central adiposity in men. Ann Epidemiol 1992; 2:
675_82.
25 Zumoff B, Strain GW, Miller LK, Rosner W, Senie R, Seres
DS, et al. Plasma free and
non-sex-hormone-binding-globulin-bound testosterone are decreased in obese men in proportion
to their degree of obesity. J Clin Endocrinol Metab 1990; 71:
929_31.
26 Pasquali R, Vicennati V, Scopinaro N, Marinari G, Simonelli
A, Flamia R, et al. Achievement of near-normal body weight
as the prerequisite to normalize sex hormone-binding globulin
concentrations in massively obese men. Int J Obes Relat Metab
Disord 1997; 21: 1_5.
27 Laughlin GA, Barrett-Connor E, Bergstrom J. Low serum
testosterone and mortality in older men. J Clin Endocrinol Metab
2008; 93: 68_75.
28 Mead JR, Irvine SA, Ramji DP. Lipoprotein lipase: structure,
function, regulation, and role in disease. J Mol Med 2002; 80:
753_69.
29 Ross R. Atherosclerosisan inflammatory disease. N Engl J
Med 1999; 340: 115_26.
30 Marin P, Oden B, Bjorntorp P. Assimilation and mobilization
of triglycerides in subcutaneous abdominal and femoral
adipose tissue in vivo in men: effects of androgens. J Clin
Endocrinol Metab 1995; 80: 239_43.
31 Rebuffe-Scrive M, Marin P, Bjorntorp P. Effect of
testosterone on abdominal adipose tissue in men. Int J Obes 1991; 15:
791_5.
32 Heeren J, Niemeier A, Merkel M, Beisiegel U.
Endothelial-derived lipoprotein lipase is bound to postprandial
triglyceride-rich lipoproteins and mediates their hepatic clearance
in vivo. J Mol Med 2002; 80: 576_84.
33 Breckenridge WC, Little JA, Steiner G, Chow A, Poapst M.
Hypertriglyceridemia associated with deficiency of
apolipo-protein C-II. N Engl J Med 1978; 298:
1265_73.
34 Brunzell JD, Miller NE, Alaupovic P, St Hilaire RJ, Wang CS,
Sarson DL, et al. Familial chylomicronemia due to a circulating
inhibitor of lipoprotein lipase activity. J Lipid Res 1983; 24:
12_9.
35 Patsch JR, Prasad S, Gotto AM Jr, Patsch W. High density
lipoprotein 2. Relationship of the plasma levels of this
lipoprotein species to its composition, to the magnitude of
postprandial lipemia, and to the activities of lipoprotein lipase and
hepatic lipase. J Clin Invest 1987; 80:
341_7.
36 Schaefer EJ, McNamara JR, Tayler T, Daly JA, Gleason JA,
Seman LJ, et al. Effects of atorvastatin on fasting and
postprandial lipoprotein subclasses in coronary heart disease patients
versus control subjects. Am J Cardiol 2002; 90:
689_96.
37 Karpe F. Postprandial lipemiaeffect of lipid-lowering drugs.
Atheroscler Suppl 2002; 3: 41_6.
38 Gwynne JT, Strauss JF 3rd. The role of lipoproteins in
steroidogenesis and cholesterol metabolism in steroidogenic
glands. Endocr Rev 1982; 3: 299_329.
39 Dobs AS, Miller S, Neri G, Weiss S, Tate AC, Shapiro DR,
et al. Effects of simvastatin and pravastatin on gonadal
function in male hypercholesterolemic patients. Metabolism 2000;
49: 115_21.
40 Stein EA, Davidson MH, Dobs AS, Schrott H, Dujovne CA,
Bays H, et al. Efficacy and safety of simvastatin 80 mg/day in
hypercholesterolemic patients. The Expanded Dose Simvastatin U.S. Study Group. Am J Cardiol 1998; 82: 311_6.
41. Karpe F, Steiner G, Uffelman K, Olivecrona T, Hamsten A.
Postprandial lipoproteins and progression of coronary
atherosclerosis. Atherosclerosis 1994; 106: 83_97.
42 Simons LA, Dwyer T, Simons J, Bernstein L, Mock P, Poonia
NS, et al. Chylomicrons and chylomicron remnants in
coronary artery disease: a case-control study. Atherosclerosis 1987;
65: 181_9.
43 Bradley WA, Gianturco SH. Triglyceride-rich lipoproteins and
atherosclerosis: pathophysiological considerations. J Intern
Med Suppl 1994; 736: 33_9.
|